OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Psychopharmacology is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up	148
Ketamine: A tale of two enantiomers	99
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science	91
Pivotal mental states	67
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD	64
Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine: Phenomenology, interpretation, and enduring effects	61
Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca	58
Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis	53
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder	53
Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin	50
A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers	48
Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches	48
Subacute effects of the psychedelic ayahuasca on the salience and default mode networks	48
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium	47
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience	46
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review	40
Associations between lifetime classic psychedelic use and markers of physical health	40
Acute subjective effects in LSD- and MDMA-assisted psychotherapy	39
Ketamine’s effect on inflammation and kynurenine pathway in depression: A systematic review	39
Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial	38
Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans	38
Psychedelics and health behaviour change	37
Does cannabis complement or substitute alcohol consumption? A systematic review of human and animal studies	36
Dose–response relationships of psilocybin-induced subjective experiences in humans	36
Modulation of microglial activation by antidepressants	36

The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration an	35
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-contro	32
A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties	31
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial	31
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study	30
The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects	30
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action	30
Neurobiological mechanisms associated with antipsychotic drug-induced dystonia	28
Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis	28
Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies	28
A narrative synthesis of research with 5-MeO-DMT	27
Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology	27
Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?	27
Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals	26
Medical cannabis in the UK: From principle to practice	26
MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults	26
Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings	25
Efficacy ofN-methyl-D-aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials	25
Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice	24
Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes	23
Rates of delirium associated with calcium channel blockers compared to diuretics, renin-angiotensin system agents and beta-blockers: An electronic health records network study	23
The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study	22
Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy	22
One (effect) size does not fit at all: Interpreting clinical significance and effect sizes in depression treatment trials	22
Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention	22
A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis	22
Pharmacological treatment of acute-phase anorexia nervosa: Evidence from randomized controlled trials	22
Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: A systematic review and network meta-analysis	21
Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial	21
In utero Δ9-tetrahydrocannabinol exposure confers vulnerability towards cognitive impairments and alcohol drinking in the adolescent offspring: Is there a role for neuropeptide Y?	21
Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms	21
Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: A meta-analysis of randomized controlled trials	21
Plasma d-glutamate levels for detecting mild cognitive impairment and Alzheimer’s disease: Machine learning approaches	20
Cannabis based medicines and cannabis dependence: A critical review of issues and evidence	20
Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca	20
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample	20
Investigating the effect of crocin on memory deficits induced by total sleep deprivation (TSD) with respect to the BDNF, TrkB and ERK levels in the hippocampus of male Wistar rats	19
Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis	19
The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs’ effects on psychological flexibility	19
A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults	19
Beyond the ‘purple drank’: Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports	19
Cannabidiol modulation of hippocampal glutamate in early psychosis	18
Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997–2019	18
An acetylcholinesterase inhibitor, donepezil, increases anxiety and cortisol levels in adult zebrafish	18
Point-of-care measurement of clozapine concentration using a finger-stick blood sample	17
Effects of repeated adolescent exposure to cannabis smoke on cognitive outcomes in adulthood	17
Rodent models for nicotine withdrawal	16
Sign tracking predicts cue-induced but not drug-primed reinstatement to methamphetamine seeking in rats: Effects of oxytocin treatment	16
Cannabis-induced oceanic boundlessness	16
LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking	16

Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension	16
Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity	16
Cannabidiol prevents priming- and stress-induced reinstatement of the conditioned place preference induced by cocaine in mice	15
Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis	15
Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania	15
Fifty years on: Serotonin and depression	14
Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study	14
Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)	14
The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers	14
Increasing recreational nitrous oxide use: Should we worry? A narrative review	14
Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: A systematic review	14
Two newly-emerging substituted phenethylamines MAL and BOD induce differential psychopharmacological effects in rodents	14
trans-Resveratrol ameliorates anxiety-like behaviors and neuropathic pain in mouse model of post-traumatic stress disorder	14
Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment	14
A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression	14
Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology	14
Development and validation of the Reward Deficiency Syndrome Questionnaire (RDSQ-29)	13
Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study	13
Treatment with slow-releasing hydrogen sulfide donors inhibits the nociceptive and depressive-like behaviours accompanying chronic neuropathic pain: Endogenous antioxidant system activation	13
AMPA receptors mediate the pro-cognitive effects of electrical and optogenetic stimulation of the medial prefrontal cortex in antidepressant non-responsive Wistar–Kyoto rats	13
Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression	13
Neural mechanisms underlying psilocybin’s therapeutic potential – the need for preclinical in vivo electrophysiology	13
Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis	13
Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate	13
Sex-dependent metabolism of ketamine and (2R,6R)-hydroxynorketamine in mice and humans	13
Brain entropy and neurotrophic molecular markers accompanying clinical improvement after ketamine: Preliminary evidence in adolescents with treatment-resistant depression	13
Hyodeoxycholic acid inhibits lipopolysaccharide-induced microglia inflammatory responses through regulating TGR5/AKT/NF-κB signaling pathway	13
Activation of the aryl hydrocarbon receptor by clozapine induces preadipocyte differentiation and contributes to endothelial dysfunction	13
Pharmacological evidence of a cholinergic contribution to elevated impulsivity and risky decision-making caused by adding win-paired cues to a rat gambling task	12
Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze	12
Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study	12
Divergent pathways mediate 5-HT_1A receptor agonist effects on close social interaction, grooming and aggressive behaviour in mice: Exploring the involvement of the oxytocin and vasopressin	12
Effects on suicidal risk: Comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder	12
Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature	12
Clinical validation of the self-reported Glasgow Antipsychotic Side-effect Scale using the clinician-rated UKU side-effect scale as gold standard reference	12
Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016	11
Oxytocin-induced facilitation of learning in a probabilistic task is associated with reduced feedback- and error-related negativity potentials	11
CB₁ receptor signalling mediates cannabidiol-induced panicolytic-like effects and defensive antinociception impairment in mice threatened by Bothrops jararaca lancehead pit vipers	11
Lithium exposure during pregnancy increases fetal growth	11
Effects of acute alcohol consumption on emotion recognition in high and low trait aggressive drinkers	11
The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment	11
The effect of metformin on cognitive function: A systematic review and meta-analysis	11
Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice	11
Nitric oxide-mediated defensive and antinociceptive responses organised at the anterior hypothalamus of mice are modulated by glutamatergic inputs from area 24b of the cingulate cortex	11
Comparative safety of chronic versus intermittent benzodiazepine prescribing in older adults: A population-based cohort study	11
Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences	11
MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinde	10
Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data	10
Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption	10
The µ-opioid system in midline thalamic nuclei modulates defence strategies towards a conditioned fear stimulus in male mice	10
Intranasal oxytocin may help maintain romantic bonds by decreasing jealousy evoked by either imagined or real partner infidelity	10
Emotional faces processing in major depressive disorder and prediction of antidepressant treatment response: A NeuroPharm study	10
Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression	10
The neurobiology of suicide in psychosis: A systematic review	10
The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls	10
Belief changes associated with psychedelic use	10
β-adrenoceptor antagonists and nightmares: A pharmacoepidemiological–pharmacodynamic study	10
Sex-specific sensitivity to methamphetamine-induced schizophrenia-relevant behaviours in neuregulin 1 type III overexpressing mice	10
The pharmacogenetics of opioid treatment for pain management	10
Mice lacking melatonin MT2 receptors exhibit attentional deficits, anxiety and enhanced social interaction	10